Primary and secondary endpoints
| Primary endpoints . | n . | % . | Missing . | Events (n) . |
|---|---|---|---|---|
| 5-y OS | 194 | 74 | ||
| 5-y EFS | 163 | 63 | ||
| Secondary endpoints | ||||
| Neutrophil recovery (day 60)* | 91 | 1 | 235 | |
| Graft-failureβ | ||||
| Primary / Secondary | 7/12 | 0 | 18/31 | |
| Chimerism (at latest follow-up) | ||||
| Full donor | 79 | 7 | 125 | |
| Mixed | 21 | 32 | ||
| Enzyme levels | ||||
| Normal | 81 | 25 | 112 | |
| < LLN (“low”) | 19 | 25 | ||
| CIF of Acute GVHD | ||||
| (Grade II-IV) | 25 | 3 | 65 | |
| (Grade III-IV) | 7 | 19 | ||
| CIF of Chronic GVHD at 5 y | 16 | 2 | 33 |
| Primary endpoints . | n . | % . | Missing . | Events (n) . |
|---|---|---|---|---|
| 5-y OS | 194 | 74 | ||
| 5-y EFS | 163 | 63 | ||
| Secondary endpoints | ||||
| Neutrophil recovery (day 60)* | 91 | 1 | 235 | |
| Graft-failureβ | ||||
| Primary / Secondary | 7/12 | 0 | 18/31 | |
| Chimerism (at latest follow-up) | ||||
| Full donor | 79 | 7 | 125 | |
| Mixed | 21 | 32 | ||
| Enzyme levels | ||||
| Normal | 81 | 25 | 112 | |
| < LLN (“low”) | 19 | 25 | ||
| CIF of Acute GVHD | ||||
| (Grade II-IV) | 25 | 3 | 65 | |
| (Grade III-IV) | 7 | 19 | ||
| CIF of Chronic GVHD at 5 y | 16 | 2 | 33 |
CIF, Cumulative incidence function; LLN, lower limit of normal.
Median days 19 (range, 9-60).